PF-07263689

AXP000105.1 · Oncolytic virus

Platform
vaccinia virus
Originator
Ignite Immunotherapy
Sponsor
Pfizer

Names

NameTypeSource
PF-07263689preferred name, codecurator, ncit

Virus

Role
Oncolytic
Family
Poxviridae
Virus
vaccinia virus (NCBI Taxonomy 10245)
Replication
conditionally replicating
Modifications
not disclosed
Source
evidence

Cross-references

NCI Thesaurus
C183114

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05061537Study of PF-07263689 in Participants With Selected Advanced Solid TumorsTerminatedPhase 12021-10-202022-10-1413Bladder Cancer; Colorectal Cancer; Head and Neck Cancer; Hepatocellular Cancer; Melanoma; Non-Small-Cell Lung Cancer; Ovarian Cancer; Renal Cell Cancer; Sarcoma; Squamous Cell Carcinoma

Recent changes

No changes recorded in its trials yet.

Notes

Oncolytic vaccinia from the Pfizer/Ignite collaboration; phase 1 with sasanlimab (NCT05061537) terminated October 2022. Construct and route not disclosed.

How to cite

PF-07263689 (AXP000105.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000105.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.